Compare YieldMax AMD Option Income Strategy ETF (AMDY) vs AstraZeneca plc (AZN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax AMD Option Income Strategy ETF vs AstraZeneca plc — how do they compare? YieldMax AMD Option Income Strategy ETF trades at $45.66, while AstraZeneca plc trades at $158.47 (market cap $248.14B). The key difference: AstraZeneca plc pays a 2.01% dividend while YieldMax AMD Option Income Strategy ETF pays none, and YieldMax AMD Option Income Strategy ETF is trading nearer its 52-week high, AstraZeneca plc nearer its low. Which is the better fit depends on your goals.
| AMDY | AZN | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $59.52 | $209.48 |
52-Week Low | $29.80 | $147.06 |
Market Cap | — | $248.14B |
Enterprise Value | — | $275.41B |
Dividend Yield | — | 2.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMDY trades at $45.66, up 2.47% with a bearish technical signal from moving averages. The ETF generates high weekly distributions but faces concerns about NAV erosion during AMD volatility. Recent Seeking Alpha analysis rates it HOLD, noting the strategy works best when AMD rises gradually rather than accelerating sharply.
Outlook remains cautious due to structural NAV erosion risks. The high-yield strategy provides income opportunity but requires careful timing. Key risks include AMD's performance volatility and the ETF's call spread strategy limitations during market downturns.
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About YieldMax AMD Option Income Strategy ETF
AMDY is an active ETF that seeks to generate weekly income by selling call options on AMD stock. It aims to provide investors with high yield while maintaining exposure to the price movements of Advanced Micro Devices.
Read more on AMDY →About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →
